Savara (SVRA) AGM 2026 summary
Event summary combining transcript, slides, and related documents.
AGM 2026 summary
4 Jun, 2026Opening remarks and agenda
Meeting called to order at 3:00 P.M. Eastern Time with executive team and auditor present.
Agenda included formal business, voting on proposals, and a Q&A session for validated stockholders.
Board and executive committee updates
Six directors nominated for re-election to serve until the 2027 annual meeting or until successors are elected.
No other nominations were received; nominations were closed.
Shareholder proposals
Proposal to elect six directors.
Proposal to amend the certificate of incorporation to increase authorized shares from 300 million to 600 million.
Proposal to amend the 2024 Omnibus Incentive Plan to increase shares authorized for issuance by 18,900,000.
Proposal to ratify RSM US LLP as independent auditor for fiscal year ending December 31, 2026.
Advisory vote on compensation of Named Executive Officers.
Latest events from Savara
- MOLBREEVI targets a 5,500-patient US market with strong launch readiness and high approval confidence.SVRA
Jefferies Global Healthcare Conference 20263 Jun 2026 - MOLBREEVI nears approval for aPAP, backed by strong data and robust launch preparations.SVRA
H.C. Wainwright 4th Annual BioConnect Investor Conference22 May 2026 - Q1 2026 net loss rose to $37.3M as regulatory filings advanced and cash reserves remained strong.SVRA
Q1 202613 May 2026 - MOLBREEVI demonstrated strong efficacy and safety in autoimmune PAP, targeting a $2B+ U.S. market.SVRA
Corporate presentation12 May 2026 - Shareholders to vote on board elections, share increase, incentive plan, and executive pay.SVRA
Proxy filing24 Apr 2026 - Key votes include director elections, share authorization increase, and auditor ratification.SVRA
Proxy filing24 Apr 2026 - MOLBREEVI nears FDA priority review, targeting August approval and rapid rare disease market entry.SVRA
Guggenheim Securities Emerging Outlook: Biotech Summit 202611 Apr 2026 - Key votes on board, capital, incentives, and auditor as company prepares for product launch.SVRA
Proxy filing10 Apr 2026 - MOLBREEVI shows strong efficacy and safety for autoimmune PAP, targeting a $2B+ U.S. market.SVRA
Corporate presentation7 Apr 2026